Supriya Lifescience Reports Strong Financial Performance Amid Evaluation Adjustment in March 2025

Supriya Lifescience, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The company has demonstrated a notable financial performance, with several key metrics reaching their highest levels in the last five quarters.
Operating Profit (PBDIT) stood at Rs 67.58 crore, reflecting a consistent upward trend. Similarly, Profit Before Tax (PBT) reached Rs 61.08 crore, and Profit After Tax (PAT) was recorded at Rs 50.38 crore, both showcasing positive momentum over the recent quarters. Additionally, net sales for the latest six months amounted to Rs 369.76 crore, marking a year-on-year growth of 23.98%. Earnings per Share (EPS) also hit a peak at Rs 6.26, indicating enhanced profitability for shareholders.

However, it is important to note that the company experienced an adjustment in its evaluation, with its score falling to 18 from 20 over the past three months. This change reflects a nuanced view of the company's overall performance, particularly in light of the highest non-operating income recorded at Rs 2.98 crore, which may not be sustainable in the long term.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.